Free Trial

Exact Sciences (EXAS) Competitors

Exact Sciences logo
$48.49 -0.28 (-0.57%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$49.11 +0.62 (+1.28%)
As of 07/25/2025 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EXAS vs. BIIB, UTHR, NBIX, INCY, EXEL, BMRN, MDGL, HALO, IONS, and RGEN

Should you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), and Repligen (RGEN). These companies are all part of the "biotechnology" industry.

Exact Sciences vs. Its Competitors

Biogen (NASDAQ:BIIB) and Exact Sciences (NASDAQ:EXAS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

In the previous week, Biogen had 26 more articles in the media than Exact Sciences. MarketBeat recorded 36 mentions for Biogen and 10 mentions for Exact Sciences. Exact Sciences' average media sentiment score of 1.22 beat Biogen's score of 0.73 indicating that Exact Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
17 Very Positive mention(s)
2 Positive mention(s)
13 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Exact Sciences
7 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Biogen has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.

Biogen has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.68B1.99$1.63B$10.1312.98
Exact Sciences$2.76B3.32-$1.03B-$5.51-8.80

Biogen has a net margin of 15.07% compared to Exact Sciences' net margin of -36.06%. Biogen's return on equity of 14.03% beat Exact Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen15.07% 14.03% 8.32%
Exact Sciences -36.06%-3.75%-1.68%

87.9% of Biogen shares are held by institutional investors. Comparatively, 88.8% of Exact Sciences shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 1.2% of Exact Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Biogen currently has a consensus target price of $186.37, suggesting a potential upside of 41.70%. Exact Sciences has a consensus target price of $70.50, suggesting a potential upside of 45.39%. Given Exact Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Exact Sciences is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
0 Sell rating(s)
21 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.34
Exact Sciences
0 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
1 Strong Buy rating(s)
2.95

Summary

Exact Sciences beats Biogen on 9 of the 17 factors compared between the two stocks.

Get Exact Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EXAS vs. The Competition

MetricExact SciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$9.20B$3.07B$5.70B$9.50B
Dividend YieldN/A2.37%4.60%4.01%
P/E Ratio-8.8021.1828.1020.05
Price / Sales3.32286.99429.3789.38
Price / Cash8.6642.7636.2258.56
Price / Book3.748.378.665.87
Net Income-$1.03B-$55.19M$3.25B$258.55M
7 Day Performance-3.90%5.88%4.22%3.73%
1 Month Performance-6.41%17.33%10.51%11.75%
1 Year Performance7.04%4.42%34.40%18.03%

Exact Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EXAS
Exact Sciences
4.7487 of 5 stars
$48.49
-0.6%
$70.50
+45.4%
+0.3%$9.20B$2.76B-8.807,000Positive News
BIIB
Biogen
4.8103 of 5 stars
$122.68
-1.8%
$186.37
+51.9%
-42.2%$18.31B$9.82B12.117,605Upcoming Earnings
Analyst Revision
UTHR
United Therapeutics
4.9917 of 5 stars
$293.12
+0.4%
$383.08
+30.7%
-9.5%$13.22B$2.88B11.701,305Trending News
Upcoming Earnings
Insider Trade
Analyst Revision
NBIX
Neurocrine Biosciences
4.5095 of 5 stars
$131.83
-0.1%
$163.87
+24.3%
-9.6%$13.05B$2.36B44.691,800Upcoming Earnings
Analyst Forecast
INCY
Incyte
4.6318 of 5 stars
$67.38
-0.7%
$74.47
+10.5%
+2.4%$13.04B$4.24B210.572,617Upcoming Earnings
Insider Trade
EXEL
Exelixis
4.7817 of 5 stars
$44.26
-0.5%
$45.28
+2.3%
+98.6%$12.07B$2.17B20.121,147News Coverage
Positive News
Upcoming Earnings
Analyst Forecast
BMRN
BioMarin Pharmaceutical
4.9857 of 5 stars
$56.56
-1.3%
$93.78
+65.8%
-31.1%$10.85B$2.85B21.033,040Positive News
Analyst Forecast
MDGL
Madrigal Pharmaceuticals
4.2732 of 5 stars
$330.94
-1.0%
$420.63
+27.1%
+5.3%$7.35B$180.13M-18.3390News Coverage
Insider Trade
HALO
Halozyme Therapeutics
4.8531 of 5 stars
$55.92
-0.9%
$62.70
+12.1%
+4.1%$6.96B$1.08B14.87390Positive News
IONS
Ionis Pharmaceuticals
4.5355 of 5 stars
$41.55
-0.5%
$57.13
+37.5%
-18.5%$6.61B$717.25M-13.901,069Upcoming Earnings
RGEN
Repligen
4.6454 of 5 stars
$114.80
-1.2%
$170.75
+48.7%
-8.0%$6.45B$650.43M-255.111,778Upcoming Earnings
Analyst Upgrade

Related Companies and Tools


This page (NASDAQ:EXAS) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners